Collegium Pharmaceutical, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M |
| Cost of Revenue | $317.3M | $254.1M | $240.6M | $254.4M | $126.3M | $130.2M | $193.7M | $165.7M |
| Gross Profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $179.8M | $103.0M | $114.7M |
| Gross Margin | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% | 34.7% | 40.9% |
| Operating Expenses | ||||||||
| Research & Development | — | $0 | $0 | $4.0M | $9.5M | $9.8M | $10.3M | $8.7M |
| SG&A Expense | $284.8M | $210.4M | $159.2M | $172.2M | $119.0M | $113.8M | $116.4M | $126.8M |
| Operating Income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | $-23.7M | $-20.7M |
| Operating Margin | 23.0% | 26.9% | 29.5% | 7.2% | 6.4% | 18.1% | -8.0% | -7.4% |
| Interest Expense | — | — | $83.3M | $63.2M | $21.0M | $28.9M | $909.0K | $20.1M |
| Pretax Income | $92.6M | $98.6M | $75.7M | $-28.8M | $-3.4M | $27.6M | $-22.7M | $-39.1M |
| Income Tax Expense | $29.7M | $29.4M | $27.6M | $-3.8M | $-74.9M | $830.0K | $0 | — |
| Net Income | $62.9M | $69.2M | $48.2M | $-25.0M | $71.5M | $26.8M | $-22.7M | $-39.1M |
| Net Margin | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% |
| EPS (Basic) | $1.98 | $2.14 | $1.43 | $-0.74 | $2.05 | $0.78 | $-0.68 | $-1.19 |
| EPS (Diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 | $0.76 | $-0.68 | $-1.19 |
| Shares Outstanding (Basic) | 31.7M | 32.3M | 33.7M | 33.8M | 34.9M | 34.4M | 33.5M | 33.0M |
| Shares Outstanding (Diluted) | 39.7M | 40.4M | 41.8M | 33.8M | 41.0M | 35.2M | 33.5M | 33.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |